Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis by Floreani A

Get full text

Familial primary biliary cirrhosis and autoimmune cholangitis. by Agarwal, K, Jones, D, Watt, F, Burt, A, Floreani, A, Bassendine, M

NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid by de Graaf, K, Lapeyre, G, Guilhot, F, Ferlin, W, Curbishley, S, Carbone, M, Richardson, P, Moreea, S, McCune, C, Ryder, S, Chapman, R, Floreani, A, Jones, D, De Min, C, Adams, D, Invernizzi, P

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases by Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease by Ji, S-G, Juran, BD, Mucha, S, Folseraas, T, Jostins, L, Melum, E, Kumasaka, N, Atkinson, EJ, Schlicht, EM, Liu, JZ, Shah, T, Gutierrez-Achury, J, Boberg, KM, Bergquist, A, Vermeire, S, Eksteen, B, Durie, PR, Farkkila, M, Müller, T, Schramm, C, Sterneck, M, Weismüller, TJ, Gotthardt, DN, Ellinghaus, D, Braun, F, Teufel, A, Laudes, M, Lieb, W, Jacobs, G, Beuers, U, Weersma, RK, Wijmenga, C, Marschall, H-U, Milkiewicz, P, Pares, A, Kontula, K, Chazouillères, O, Invernizzi, P, Goode, E, Spiess, K, Moore, C, Sambrook, J, Ouwehand, WH, Roberts, DJ, Danesh, J, Floreani, A, Gulamhusein, AF, Eaton, JE, Schreiber, S, Chapman, RW, Et al.